Advancing Breakthroughs in Neuroscience to Elevate Life
Fighting Disease So More “You” Shines Through
At Acadia, we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We have developed therapies for the treatment of Rett syndrome and for hallucinations and delusions associated with Parkinson’s disease psychosis. Currently, our clinical-stage developments focus on addressing Prader-Willi syndrome, Alzheimer’s disease psychosis, and neuropsychiatric symptoms in CNS disorders.
We recently announced that Health Canada has granted market authorization for our treatment of Rett syndrome in adult and pediatric patients two years of age and older. Learn more here.
Our Purpose
We fight disease so more you shines through
Our Mission
Elevate Life
Our Values
We fight for patients to elevate life through science
We are driven by innovation to forge a healthy future
We are family, united through collaboration and diverse perspectives
We are determined, we break through barriers, we persevere
We take our work seriously, but not ourselves
Leading the Way in Rett Syndrome Therapy
Our commitment is unwavering towards creating a brighter future for individuals living with rare diseases and their families. Our efforts continue to focus on broadening access to essential therapies for families across the globe.
Canada News
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Contact Us
General Inquiries
info@acadia-pharm.com
Medical Information
medicalinformationcanada@acadia-pharm.com
Media Inquiries
media@acadia-pharm.com
Phone
(844) ACADIA-1
Address
295 Robinson St., Suite 100
Oakville, Ontario L6J 1G7
